Company Overview and News


Add 0801
to your dashboard

Headline News

China Cord Blood's (CO) Management on Q2 2018 Results - Earnings Call Transcript

2017-11-21 seekingalpha
Welcome everyone to China Cord Blood Corporation Earnings Conference Call for the Second Quarter of Fiscal 2018. All participants' lines will be placed on mute during the presentation after which there will be a question-and-answer session. This conference is being recorded. (2-0)

Golden Meditech Announces FY2016/2017 Annual Results

2017-06-28 devicespace
Golden Meditech Holdings Limited (SEHK stock code: 00801, TWSE stock code: 910801) ("Golden Meditech" or the "Company", together with its subsidiaries, the "Group"), a leading integrated healthcare enterprise in China, announces today its annual results for the year ended 31 March 2017 (the "Year" or "FY2016/2017").

China Cord Blood (CO) Q4 2017 Results - Earnings Call Transcript

2017-06-22 seekingalpha
Welcome everyone to China Cord Blood Corporation's Earnings Conference Call for the Fourth Quarter and Full year of Fiscal 2017. All participants' lines will be placed on mute during the presentation after which there will be a question-and-answer session.

Golden Meditech Announces The Close Of The Voluntary Conditional Cash Offer And Remains Public

2017-04-10 devicespace
HONG KONG, April 10, 2017 /PRNewswire/ -- Golden Meditech Holdings Limited (SEHK stock code: 00801, TWSE stock code: 910801) ("Golden Meditech" or the "Company"), a leading integrated healthcare enterprise in China, today announced that the voluntary conditional cash offer made by Mr. Kam Yuen, the Chairman, executive director and controlling shareholder of the Company, through his controlled company -- Magnum Opus 3 International Holdings Limited ("MO3") closed on 10 April 2017.

Golden Meditech Announces the Close of the Voluntary Conditional Cash Offer and Remains Public

2017-04-10 prnewswire
HONG KONG, April 10, 2017 /PRNewswire/ -- Golden Meditech Holdings Limited (SEHK stock code: 00801, TWSE stock code: 910801) ("Golden Meditech" or the "Company"), a leading integrated healthcare enterprise in China, today announced that the voluntary conditional cash offer made by Mr. Kam Yuen, the Chairman, executive director and controlling shareholder of the Company, through his controlled company -- Magnum Opus 3 International Holdings Limited ("MO3") closed on 10 April 2017.

Golden Meditech Announces The Condition To The Voluntary Conditional Cash Offer Has Been Satisfied

2017-03-15 devicespace
HONG KONG, March 15, 2017 /PRNewswire/ -- Golden Meditech Holdings Limited (SEHK stock code: 00801, TWSE stock code: 910801) ("Golden Meditech" or the "Company"), a leading integrated healthcare enterprise in China, today announced that the shareholding ratio condition to the voluntary conditional cash offer made by Mr. Kam Yuen, the Chairman, executive director and controlling shareholder of the Company, through his controlled company -- Magnum Opus 3 International Holdings Limited ("MO3") has been satisfied, as a result, the voluntary conditional cash offer is now unconditional.

China Cord Blood (CO) Q3 2017 Results - Earnings Call Transcript

2017-02-27 seekingalpha
Welcome everyone to China Cord Blood Corporation's Earnings Conference Call for the Third Quarter of Fiscal 2017. Today's conference is being recorded. All participants' lines will be placed on mute during the presentation after which there will be a question-and-answer session.

China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2017

2017-02-24 prnewswire
HONG KONG, Feb. 24, 2017 /PRNewswire/ -- China Cord Blood Corporation (NYSE: CO) ("CCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced its unaudited financial results for the third quarter and first nine months of fiscal year 2017 ended December 31, 2016.

Golden Meditech To Sell Its Equity Interest In China Cord Blood For Cash Consideration Of RMB5.764 Billion

2016-12-30 devicespace
HONG KONG, Dec. 30, 2016 /PRNewswire/ -- Golden Meditech Holdings Limited (SEHK stock code: 00801, TWSE stock code: 910801) ("Golden Meditech" or the "Company", together with its subsidiaries, the "Group"), a leading integrated healthcare enterprise in China, announces that it entered into a sale and purchase agreement with Nanjing Yingpeng Huikang Medical Industry Investment Partnership (Limited Partnership) 1 ("Yingpeng Huikang Fund" or the "Purchaser") on 30 December 2016 regarding the disposal of the Company's entire equity stake in China Cord Blood Corporation ("CCBC") which represents 65.

Golden Meditech to Sell 65.4% Stake in China Cord Blood for $0.83B

2016-12-30 genengnews
Advances in Genome Sequencing, Pharmacogenomics, Gene Editing, and Biometric Wearables Will Provide New Pathways to Better Health

CORRECTED-BRIEF-Golden Meditech to sell its equity interest in China Cord Blood Corp

2016-12-30 feeds.reuters
(Corrects headline to "... to sell its equity interest in China Cord Blood Corp", from ".... to sell its equity interest in China")

CORRECTED-BRIEF-Golden Meditech to sell its equity interest in China Cord Blood Corp

2016-12-30 feeds.reuters
(Corrects headline to "... to sell its equity interest in China Cord Blood Corp", from ".... to sell its equity interest in China")

Golden Meditech to Sell its equity Interest in China Cord Blood Corporation for Cash Consideration of RMB5.764 Billion

2016-12-30 prnewswire
HONG KONG, Dec. 30, 2016 /PRNewswire/ -- Golden Meditech Holdings Limited (SEHK stock code: 00801, TWSE stock code: 910801) ("Golden Meditech" or the "Company", together with its subsidiaries, the "Group"), a leading integrated healthcare enterprise in China, announces that it entered into a sale and purchase agreement with Nanjing Yingpeng Huikang Medical Industry Investment Partnership (Limited Partnership) 1 ("Yingpeng Huikang Fund" or the "Purchaser") on 30 December 2016 regarding the disposal of the Company's entire equity stake in China Cord Blood Corporation ("CCBC") which represents 65.

Golden Meditech Announces FY2016/2017 Interim Results

2016-11-23 devicespace
Loss before interest, tax, depreciation and amortisation, fair value changes in financial assets and financial liabilities

Golden Meditech Announces FY2016/2017 Interim Results

2016-11-23 prnewswire
Proactively Adjusts Marketing Strategy to Cope with the Fluctuation in Medical Devices Business Development of Healthcare Services Business On-track, Sunbow O&G Hospital to Contribute New Momentum